Literature DB >> 20838838

Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature.

Daniel Q Sun1, Jennifer J Cheng, James L Frazier, Sachin Batra, Gary Wand, Lawrence R Kleinberg, Daniele Rigamonti, Alfredo Quinones-Hinojosa, Roberto Salvatori, Michael Lim.   

Abstract

Fractionated radiotherapy (FRT) and gamma knife stereotactic radiosurgery (GKSRS) are used as adjuvant therapies to surgical resection for functional and non-functional pituitary adenomas, although their optimum role in the treatment algorithm, as well as long-term safety and efficacy, still awaits further study. We report a single center experience with 33 patients with non-functional (16 patients), ACTH- (five patients), GH- (four patients), or prolactin-secreting (eight patients) tumors treated with FRT or SRS. The median tumor diameter was 1.9 cm, and the median follow-up was 36 months. For GKSRS, the median dosage was 16 Gy for non-functional adenomas and 23 Gy for hormone-secreting tumors. The median total dose for FRT was 50.4 Gy over 28 fractions (median). Two patients (6%) demonstrated radiographic evidence of tumor progression, three patients (9%) demonstrated radiation-induced visual field deficits on neuro-ophthalmic evaluation, and two patients (6%) suffered from radiation-induced hypopituitarism. Biochemical control, defined as normalized hormone values in the absence of medical therapy, was achieved in five out of eight prolactinoma patients and two out of five patients with Cushing's disease, but none of the four patients with acromegaly. These results are presented with a review of the relevant literature on the differential characteristics of FRT versus SRS in the treatment of functional and non-functional pituitary adenomas and validate postoperative irradiation as a potentially safe and effective means for tumor control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838838     DOI: 10.1007/s10143-010-0285-2

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  38 in total

1.  Gamma knife radiosurgery for medically and surgically refractory prolactinomas.

Authors:  Nader Pouratian; Jason Sheehan; Jay Jagannathan; Edward R Laws; Ladislau Steiner; Mary L Vance
Journal:  Neurosurgery       Date:  2006-08       Impact factor: 4.654

2.  Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery.

Authors:  C Höybye; E Grenbäck; T Rähn; M Degerblad; M Thorén; A L Hulting
Journal:  Neurosurgery       Date:  2001-08       Impact factor: 4.654

3.  The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

Authors:  J Estrada; M Boronat; M Mielgo; R Magallón; I Millan; S Díez; T Lucas; B Barceló
Journal:  N Engl J Med       Date:  1997-01-16       Impact factor: 91.245

4.  The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

Authors:  Giuseppe Minniti; Marie-Lise Jaffrain-Rea; Mattia Osti; Vincenzo Esposito; Antonio Santoro; Francesca Solda; Patrizia Gargiulo; Guido Tamburrano; Riccardo Maurizi Enrici
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

5.  Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.

Authors:  G Barrande; M Pittino-Lungo; J Coste; D Ponvert; X Bertagna; J P Luton; J Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

6.  Pituitary adenomas treated with gamma knife radiosurgery: volumetric analysis of 100 cases with minimum 3 year follow-up.

Authors:  M Necmettin Pamir; Türker Kiliç; Muhittin Belirgen; Ufuk Abacioğlu; Nural Karabekiroğlu
Journal:  Neurosurgery       Date:  2007-08       Impact factor: 4.654

7.  Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions.

Authors:  John R Adler; Iris C Gibbs; Putipun Puataweepong; Steven D Chang
Journal:  Neurosurgery       Date:  2008-02       Impact factor: 4.654

8.  The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma.

Authors:  Marco Losa; Lorenzo Gioia; Piero Picozzi; Alberto Franzin; Micol Valle; Massimo Giovanelli; Pietro Mortini
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

9.  Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking.

Authors:  Marco Losa; Micol Valle; Pietro Mortini; Alberto Franzin; Camillo Ferrari da Passano; Marco Cenzato; Stefania Bianchi; Piero Picozzi; Massimo Giovanelli
Journal:  J Neurosurg       Date:  2004-03       Impact factor: 5.115

10.  Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.

Authors:  Bruce E Pollock; Jeffrey T Jacob; Paul D Brown; Todd B Nippoldt
Journal:  J Neurosurg       Date:  2007-05       Impact factor: 5.115

View more
  8 in total

Review 1.  Radiotherapy for prolactin-secreting pituitary tumors.

Authors:  Lawrence J Sheplan Olsen; Lizbeth Robles Irizarry; Samuel T Chao; Robert J Weil; Amir H Hamrahian; Betul Hatipoglu; John H Suh
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 2.  Treatment of hyperprolactinemia: a systematic review and meta-analysis.

Authors:  Amy T Wang; Rebecca J Mullan; Melanie A Lane; Ahmad Hazem; Chaithra Prasad; Nicola W Gathaiya; M Mercè Fernández-Balsells; Amy Bagatto; Fernando Coto-Yglesias; Jantey Carey; Tarig A Elraiyah; Patricia J Erwin; Gunjan Y Gandhi; Victor M Montori; Mohammad Hassan Murad
Journal:  Syst Rev       Date:  2012-07-24

3.  Long-term outcomes of acromegaly treated with fractionated stereotactic radiation: case series and literature review.

Authors:  Ryan Rhome; Isabelle M Germano; Ren-Dih Sheu; Sheryl Green
Journal:  Neurooncol Pract       Date:  2017-03-31

4.  Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas.

Authors:  Stefan Rieken; Daniel Habermehl; Thomas Welzel; Angela Mohr; Katja Lindel; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2013-01-23       Impact factor: 3.481

5.  Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors.

Authors:  Arnar Astradsson; Anne Katrine Wiencke; Per Munck af Rosenschold; Svend-Aage Engelholm; Lars Ohlhues; Henrik Roed; Marianne Juhler
Journal:  J Neurooncol       Date:  2014-02-15       Impact factor: 4.130

6.  Risk-adapted single or fractionated stereotactic high-precision radiotherapy in a pooled series of nonfunctioning pituitary adenomas: high local control and low toxicity.

Authors:  Jan Patrick Boström; Almuth Meyer; Bogdan Pintea; Rüdiger Gerlach; Gunnar Surber; Guido Lammering; Klaus Hamm
Journal:  Strahlenther Onkol       Date:  2014-08-05       Impact factor: 3.621

7.  Deferred Radiotherapy After Debulking of Non-functioning Pituitary Macroadenomas: Clinical Outcomes.

Authors:  Sarah E Nicholas; Roberto Salvatori; Alfredo Quinones-Hinojosa; Kristin Redmond; Gary Gallia; Michael Lim; Daniele Rigamonti; Henry Brem; Lawrence Kleinberg
Journal:  Front Oncol       Date:  2019-01-10       Impact factor: 6.244

8.  Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up.

Authors:  Kerstin A Kessel; Christian D Diehl; Markus Oechsner; Bernhard Meyer; Jens Gempt; Claus Zimmer; Friederike Schmidt-Graf; Stephanie E Combs
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.